HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $14 Price Target
HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $14 Price Target
HC Wainwright & Co.重申買入Reviva Pharmaceuticals，維持14美元的目標價。
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $14 price target.
HC Wainwright & Co. 分析師Raghuram Selvaraju 重申 Reviva Pharmaceuticals (納斯達克:RVPH) 買入評級，維持目標價14美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。